94236-20-1

Upstream product

• 18982-54-2 o-bromobenzyl alcohol 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 22115-41-9 2-(bromomethyl)benzonitrile 
• 1391828-93-5 C₁₀H₁₂O₂ 
• 1394295-61-4 C₂₆H₃₀O₇ 
• 1394295-55-6 C₂₁H₃₂O₃Si 
• 1394295-45-4 C₃₀H₄₁FO₃Si 
• 1394295-39-6 C₂₇H₃₆O₃Si 
• 1394295-37-4 C₃₀H₄₂O₃Si 
• 1394295-32-9 C₂₅H₄₀O₃Si 
• 1187820-70-7 6-[2-[(tert-butyldimethylsilanyl)oxymethyl]phenyl]-2-chloroimidazo[1,2-a]pyridine 
• 1187820-72-9 [2-[2-(Furan-3-yl)imidazo[1,2-a]pyridin-6-yl]phenyl]methanol 
• 1187820-71-8 6-[2-[(tert-Butyldimethylsilanyl)oxymethyl]phenyl]-2-(furan-3-yl)imidazo[1,2-a]pyridine 
• 1173102-10-7 tert-butyldimethylsilyl 2-(methylselenyl)benzyl ether 
• 221543-24-4 2-(tert-butyldimethylsilyloxymethyl)phenylmagnesium bromide 
• 240122-06-9 5-[2-(tert-butyl)dimethylsilyloxymethyl-phenyl]-2-vinyl-furan 

Relevant academic research and scientific papers

Intramolecular nonbonded interactions between divalent selenium centers with donor and acceptor substituents

To investigate the intramolecular van der Waals interactions between two divalent selenium, centers in the solid state and in solution, we have prepared methyl 2-(methylselenyl)benzyl selenide (1), ethynyl 2-(methylselenyl)benzyl selenide (2), and 2-(meth

Design of spontaneously blinking fluorophores for live-cell super-resolution imaging based on quantum-chemical calculations

Spontaneously blinking fluorophores are powerful tools for live-cell super-resolution imaging under physiological conditions. Here we show that quantum-chemical calculations can predict key parameters for fluorophore design. We applied this methodology to

Macrocyclic MCL-1 inhibitors and methods of use

The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

Synthetic method of 2-cyanobenzyl bromide and analogues thereof

The invention discloses a synthetic method of 2-cyanobenzyl bromide and analogues thereof. The synthetic method comprises the following steps: 1) using a compound I as a raw material, conducting reaction on the compound I and tert-butyldimethylsilyl chloride, and adding a first solvent and an acid-binding agent to generate a compound II; 2) dissolving the compound II into a second solvent, adding a palladium catalyst and a cyaniding agent, and carrying out a cyaniding reaction to generate a compound III; 3) dissolving the compound III into a third solvent without taking off protecting groups, and directly carrying out a bromination reaction under the effect of phosphorus tribromide so as to prepare a compound IV. The synthetic method is simple in process route and relatively high in product quality and yield.

A mild and highly efficient method for the preparation of silyl ethers using Fe(HSO4)3/Et3N by chlorosilanes

Avery efficient and mild procedure for preparation of silyl ethers from benzylic, allylic, propargilic alcohols, phenols, naphtoles and some of phenolic drugs with trimethylsilylchloride (TMSCl), triethylsilylchloride (TESCl) and t-buthyldimethylsilyl chloride (TDSCl) ethers in the presence of Fe(HSO 4)3/Et3N in roomtemperature in excellent yields is reported. This procedure also allows the excellent selectivity for silylation of alcohols and phenols.

POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF

Compounds of formula (I): wherein R, R1, R2, R3, R4 and X are as defined in the disclosure, or an acid addition salt thereof, and the therapeutic use and process of synthesis thereof.

Calcium receptor antagonist

A compound of the formula [I] wherein R1 is optionally substituted aryl group or optionally substituted heteroaryl group; R2 is optionally substituted C1-6 alkyl group, C3-7 cycloalkyl group and the like; R3 is hydrogen atom, C1-6 alkyl group, hydroxyl group and the like; R4 is hydrogen atom, C1-6 alkyl group and the like; R5 and R6 are each C1-6 alkyl group and the like; R7 is optionally substituted aryl group or optionally substituted heteroaryl group; X1, X2 and X3 are each C1-6 alkylene group and the like; and X4 and X5 are each a single bond, methylene group and the like, a salt thereof, a solvate thereof or a prodrug thereof, and a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic agent for osteoporosis, are provided. The compound of the present invention is useful as a therapeutic drug of diseases accompanied by abnormal calcium homeostasis, or osteoporosis, hypoparathyreosis, osteosarcoma, periodontal disease, bone fracture, steoarthrosis, chronic rheumatoid arthritis, Paget's disease, humoral hypercalcemia, autosomal dominant hypocalcemia and the like. In addition, an intermediate for the compound is provided.